| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 72.0 | 53.8 |
| Gross profit | 49.7 | 37.7 |
| Profit before tax | -10.1 | -10.7 |
| Net income | -10.7 | -11.1 |
| EPS (diluted, $ a share) | $-0.35 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +33.9% |
|---|---|
| Gross margin | 69.1% |
| Operating margin | -3.6% |
10-Q filed with the SEC, NASDAQ: ESTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Establishment Labs Holdings Inc.: key numbers
- Share price
- $69.82Close, Nov 16
- Market cap
- $2.08B
- Shares outstanding
- 29.82MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Establishment Labs Holdings Inc.
All →Establishment Labs Holdings Financial Results
Establishment Labs reported Q3 2026 revenue of $72.0 million, a 33.9% increase year-over-year, driven by 119% growth in the U.S. market. The company achieved its first-ever quarter of positive operating and free cash flow and raised its full-year 2026 revenue guidance to over $274 million.
- Term
- Q3 2026
“Third-quarter results reflect strong global revenue growth, increasing operating leverage and an important milestone in cash generation as we invest in innovation and commercial expansion.”
Peter Caldini, Chief Executive Officer
“We enter 2027 with a strong financial foundation and with significant opportunities and growth ahead of us, especially in minimally invasive and reconstruction. We expect fiscal 2027 to deliver growth of 25% and positive cash flow, setting the stage for many years to come.”
Peter Caldini, Chief Executive Officer
Establishment Labs Holdings Business Update
Establishment Labs Holdings Inc. entered into an amendment to its Master Supply Agreement with NuSil Technology LLC, extending the contract term from December 31, 2026, to December 31, 2031. The agreement secures the supply of medical-grade silicone for the company's products and includes updated terms for pricing, business continuity, and intellectual property.
- Counterparty
- NuSil Technology LLC
- Term
- 5 years